• LAST PRICE
    14.8494
  • TODAY'S CHANGE (%)
    Trending Up0.6794 (4.7946%)
  • Bid / Lots
    14.2200/ 1
  • Ask / Lots
    16.4500/ 2
  • Open / Previous Close
    14.4500 / 14.1700
  • Day Range
    Low 14.4500
    High 15.0000
  • 52 Week Range
    Low 6.6900
    High 47.1700
  • Volume
    10,344
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 14.17
TimeVolumeENGN
10:21 ET20014.45
10:24 ET40014.9133
10:28 ET10014.75
10:30 ET10015
11:38 ET20014.9999
01:10 ET10014.75
03:50 ET20014.95
03:52 ET10014.95
03:54 ET50014.7
03:56 ET20014.8
03:57 ET36214.84
03:59 ET130514.8494
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesENGN
enGene Holdings Inc
647.2M
-3.2x
---
United StatesCABA
Cabaletta Bio Inc
643.5M
-8.1x
---
United StatesCOGT
Cogent Biosciences Inc
641.6M
-2.8x
---
United StatesNUVB
Nuvation Bio Inc
641.4M
-7.5x
---
United StatesSVRA
Savara Inc
664.5M
-14.0x
---
United StatesLBPH
Longboard Pharmaceuticals Inc
628.3M
-7.3x
---
As of 2024-04-20

Company Information

enGene Holdings Inc. is a holding company. The Company, through its subsidiary, enGene Inc., is engaged in developing non-viral gene therapies based on localized delivery of nucleic acid payloads to mucosal tissues. The Company’s proprietary dually derived chitosan (DDX) platform has a high degree of payload flexibility, including DNA and various forms of RNA with broad tissue and disease application. In preclinical animal and in vitro models, the Company’s DDX technology has been demonstrated to effectively induce expression of therapeutic genes following delivery to the lung, gastrointestinal tract, and urinary tract, and its lead product detalimogene voraplasmid (EG-70) is being developed for the treatment of bacillus calmette-guerin (BCG)-resistant non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS). EG-70 is a novel non-viral gene therapy designed to elicit a local immune response following the delivery to the bladder urothelium.

Contact Information

Headquarters
4868 Rue Levy, Suite 220SAINT-LAURENT, QC, Canada H4R 2P1
Phone
514-332-4888
Fax
---

Executives

President, Chief Operating Officer
Alexander Nichols
Chief Executive Officer, Director
Jason Hanson
Chief Financial Officer, Head - Business Development
Ryan Daws
Chief Technology Officer
Anthony Cheung
Chief Scientific Officer
James Sullivan

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$647.2M
Revenue (TTM)
$0.00
Shares Outstanding
43.6M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-4.60
Book Value
$3.12
P/E Ratio
-3.2x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.